focus -WSS

focus

author：explore 2025-09-27 13:03:37 - browse：2

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Big Tobacco's 'harm reduction': Is it for real, or a sham?

WSS

Biohaven protein

Health insurers say they are turning to AI to cut costs, improve care

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Military medical care influenced by rank and race, new study finds

AI used to predict Covid

Biohaven protein

focus

focus

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Do more moles mean more problems? Not so, says new study

The high cost of giving birth even with insurance

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Guidelines to prevent youth baseball injuries need more muscle

Second House panel advances two

Activists slam private health insurers over coverage restrictions

Focused ultrasound for uterine fibroids: an uphill battle

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Do more moles mean more problems? Not so, says new study

focus

Readers respond to H5N1 and livestock movements, and more

With measles on the rise, a personal story of a devastating disease

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Dark money group runs ads on China biotech bill

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

focus

entertainment

hotspot

entertainment